L9294

Anti-LRP6 antibody produced in rabbit

~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution

• Synonym(s): Anti-ADCAD2, Anti-CD, Anti-Coronary artery disease, autosomal dominant 2, Anti-Low-density lipoprotein receptor-related protein 6
• UNSPSC Code: 12352203

Properties

• biological source: rabbit
• conjugate: unconjugated
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: polyclonal
• form: buffered aqueous solution
• mol wt: antigen ~180 kDa
• species reactivity: human
• packaging: antibody small pack of 25 μL
• enhanced validation: recombinant expression; Learn more about Antibody Enhanced Validation
• concentration: ~1.5 mg/mL
• technique(s): immunoprecipitation (IP): 5-10 μg using lysate of HEK-293T cells expressing human LRP6; western blot: 1-2 μg/mL using lysate of HEK-293T cell expressing human LRP6.
• UniProt accession no.: O75581
• shipped in: dry ice
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... LRP6(4040) ; mouse ... Lrp6(16974) ; rat ... Lrp6(312781)

Description

General description

Low-density lipoprotein receptor-related protein 6 (LRP6) belongs to the low-density lipoprotein receptor (LDLR) family and is expressed majorly in the nervous system. It is closely related to LRP5. LRP6 gene is mapped to human chromosome 12p13.2.

Specificity

Anti-LRP6 specifically recognizes human LRP6.

Application

Anti-LRP6 antibody produced in rabbit may be used in immunoblotting and immunoprecipitation.

Biochem/physiol Actions

Low-density lipoprotein receptor related protein 6 (LRP6) is part of the wingless (Wnt)-frizzled-LRP6 complex, that recruits axin to the plasma membrane. This results in the inhibition of beta-catenin phosphorylation and subsequent degradation and activation of T-cell factor/lymphoid enhancer-binding factor 1 (TCF/LEF-1)-dependent transcription. LRP6 is essential for proper brain development. Deletion of the LRP6 gene results in severe brain abnormalities. Mutations in LRP6 are associated with coronary heart disease and osteoporosis. LRP6 has been shown to undergo phosphorylation at multiple PPPSP motifs upon stimulation by Wnt. The phosphorylation of LRP6 by glycogen synthase kinase 3 (GSK3) and casein kinase 1 (CKI) is induced by Wnt. Regulated proteolytic processing of LRP6 has shown to release its intracellular domain (ICD). This fragment binds to GSK3 and inhibits its activity, resulting in activation of the canonical Wnt signaling pathway. A higher expression of LRP6 is detected in tumors.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Storage and Stability

Store at –20 °C. For continuous use, the product may be stored at 2–8 °C for up to one month. For extended storage, freeze in working aliquots at –20 °C. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.